Protocol Ledger

NCT03952091 · Phase III · COMPLETED

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Interventional Phase III clinical trial protocol NCT03952091 sponsored by TJ Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-27 Enrollment: 289 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03952091
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)289 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03952091
Protocol FieldVerified Registry Value
NCT IdentifierNCT03952091
Consolidated Lead SponsorTJ Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment289 participants (ACTUAL)
Registered Start Date2019-03-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI